We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Sell-by date

29 July 2019 By Jennifer Saba

The $240 bln pharma outfit is spinning its off-patent arm and merging it with Mylan. Combining brands like Lipitor and Viagra with EpiPen creates scale but generic price pressure makes for a poor financial prognosis. Pfizer at least gets $12 bln to spend on innovative new drugs.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)